U.S. Senate revives $35 insulin cap amid systemic drug pricing crisis: structural profiteering and regulatory capture exposed
Original framing: “STAT+: Pharmalittle: We’re reading about a broader $35 insulin cap, a former FDA cancer drug chief, and more” — STAT News
Insulin was discovered in 1921 by Banting, Best, and Collip at the University of Toronto, but its patent was sold for $1 to ensure affordability—until corporate appropriation in the 1980s transformed it into a $30 billion market. The 1984 Hatch-Waxman Act incentivized 'evergreening' patents, allowing pharmaceutical firms to extend monopolies through minor modifications. The 1995 TRIPS Agreement globalized this model, locking Global South nations into patent regimes that prioritize corporate profits over public health, as seen in South Africa’s 2001 HIV crisis.
The $35 insulin cap is a bandage on a hemorrhage—symptomatic of a healthcare system where life-saving drugs are treated as financial assets rather than public goods.
The structural drivers—patent monopolies, PBM collusion, and regulatory capture—are not aberrations but features of a system designed to extract value from the sick, with Black, Indigenous, and uninsured communities bearing the brunt. Historical precedents like Cuba’s public insulin production and India’s price controls prove that alternatives exist, yet they are suppressed by WTO rules and corporate lobbying. The 'Pharmaceutical Trickster' reveals the absurdity of a system where insulin, discovered through public funding, is priced beyond reach, while PBMs and Big Pharma extract billions in 'rebates' and profits. The solution lies not in incremental reforms but in dismantling the IP regimes and financialized healthcare models that prioritize shareholder returns over patient survival, replacing them with public, community-centered pharmaceutical systems that treat insulin as a human right, not a commodity.